drugset
drugset / Trial / NCT02806804

Safety and Immunogenicity Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged Years 3-60

NCT02806804 ↗

Phase 3 Unknown 2400 enrolled Beijing Chaoyang District Centre for Disease Control and Prevention
RandomizedSingle-groupDouble-blindPrevention

Summary

This study evaluates the safety and immunogenicity of the quadrivalent influenza virus vaccine in healthy people aged years 3-60.Subjects will be randomly divided into 3 groups,receiving the test vaccine, commercially available trivalent influenza vaccine and trivalent influenza vaccine containing new influenza B component respectively. Each group has 800 subjects,2400 in total.

Timeline

Start
2016-05
Primary completion
2016-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Quadrivalent Influenza Virus Vaccine Vaccine — —
Subject commercially available trivalent influenza vaccine Vaccine — —
Subject test vaccine Vaccine — —

Indications

No indication recorded.